Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib and Cetrelimab as Neoadjuvant Treatment for MIBC (SOGUG-NEOWIN)
NCT06511648Phase 2Recruiting
- Sponsor
- SOGUG
- Start
- Mar 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of erdafitinib in Muscle Invasive Bladder Cancer (MIBC), sponsored by SOGUG. Started Mar 2023; status: recruiting.
02
Drugs
erdafitinib
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Beyond the preview
Go deeper on NCT06511648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511648.